Association between intravitreal anti-vascular endothelial growth factor agents and respiratory events: a meta-analysis.

Key Points

• The aim is to evaluate the safety of intravitreal anti-VEGF agents and their association with respiratory events like COPD.
• Conducted a meta-analysis of randomized controlled trials (RCTs)
• Compared the incidence of COPD with anti-VEGF to sham injections
• Assessed the variability of respiratory event reporting across studies
• No significant difference in the risk of COPD was found with anti-VEGF agents versus sham injections
• Observed differences in respiratory events were variable and should be interpreted cautiously